LABCORP HOLDINGS INC.

LH 10-K · Q4 2025
API behind this page

LH Q4 2025 request

Playground key active
Request URL /api/financials?ticker=LH&year=2025&quarter=4
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q4 2025 Q4 2024 YoY
Revenue 3,515.8 3,329.4 +5.6%
Show Business Segments breakouts
Biopharma Laboratory Services · Operating Segments 793 767 +3.4%
Diagnostics [Member] · Operating Segments 2,728.5 2,586.2 +5.5%
Show Consolidation Items breakouts
Intersegment Elimination 5.7 23.8 -76.1%
Cost of Revenue 2,522.6 2,433.1 +3.7%
Gross Profit 993.2 896.3 +10.8%
Selling, General & Administrative 538.6 595.2 -9.5%
Amortization Of Intangible Assets 72.6 70.4 +3.1%
Asset Impairment Charges 3.6 2.8 +28.6%
Operating Income 267.6 216.5 +23.6%
Show Business Segments breakouts
Biopharma Laboratory Services · Operating Segments 136.1 130.7 +4.1%
Corporate -100.7 -189.1 +46.7%
Diagnostics [Member] · Operating Segments 419.2 359.5 +16.6%
Show Consolidation Items breakouts
Operating Segments 555.3 490.2 +13.3%
Interest Expense -55 -63.4 +13.2%
Investment Income Net 3.5 15 -76.7%
Income Loss From Equity Method Investments -6.1 -0.7 -771.4%
Other Non-Operating Income (Expense) -19.4 16.4 -218.3%
Income Lossfrom Continuing Operations Before Income Taxesand Noncontrolling Interest 190.6 183.8 +3.7%
Income Tax Expense (Benefit) 25.7 40.2 -36.1%
Net Income 164.9 143.6 +14.8%
Net Income Loss Attributable To Noncontrolling Interest -0.2 -0.2 0.0%
Net Income 164.7 143.4 +14.9%
EPS (Basic) 2 1.72 +16.3%
EPS (Diluted) 1.98 1.71 +15.8%
Comprehensive Income 179.1 -5 +3682.0%
Wtd Avg Shares (Basic) -0.2 -0.1 -100.0%
Wtd Avg Shares (Diluted) -0.2 -0.1 -100.0%
Labor And Related Expense (Q) — — —
Show Business Segments breakouts
Biopharma Laboratory Services 315.8 296.1 +6.7%
Diagnostics [Member] 1,208.3 1,164.1 +3.8%

Balance Sheet

Balance Sheet
Metric Q4 2025 Q4 2024 YoY
Current Assets
Cash & Cash Equivalents 532.3 1,518.7 -65.0%
Accounts Receivable 2,103.8 1,944.1 +8.2%
Unbilled Contracts Receivable 156.9 152.9 +2.6%
Inventory 534.7 493.2 +8.4%
Prepaid Expenses & Other Current Assets 692.8 697.6 -0.7%
Total Current Assets 4,020.5 4,806.5 -16.4%
Non-Current Assets
Property, Plant & Equipment 3,081.5 3,045.4 +1.2%
Show Geography breakouts
Europe 370.4 355.5 +4.2%
North America 2,587.1 2,576.1 +0.4%
Other countries [Member] 124 113.8 +9.0%
Goodwill 6,789.5 6,369.7 +6.6%
Show Business Segments breakouts
Biopharma Laboratory Services 1,354.7 1,267.2 +6.9%
Diagnostics [Member] 5,434.8 5,102.5 +6.5%
Other Non-Current Assets 751.3 652.2 +15.2%
Total Assets 18,392.7 18,379 +0.1%
Operating Lease Right-of-Use Assets 803.9 784.5 +2.5%
Intangible Assets 3,036.8 2,931.4 +3.6%
Show Finite Lived Intangible Assets By Major Class breakouts
Customer Relationships 2,709 2,574 +5.2%
Noncompete Agreements 105.5 96.3 +9.6%
Other Intangible Assets 11.1 18.4 -39.7%
Patents, Licenses And Technology [Member] 211.2 242.7 -13.0%
Other Assets
Intangible Assets Net Excluding Goodwill 3,596 3,488.9 +3.1%
Investments In Affiliates Subsidiaries Associates And Joint Ventures 153.9 16.3 +844.2%
Current Liabilities
Accounts Payable 840.8 875.8 -4.0%
Accrued Liabilities 847.8 871.2 -2.7%
Deferred Revenue 439.1 392.2 +12.0%
Operating Lease Liability Current 191.1 184.6 +3.5%
Finance Lease Liability Current 4.6 6.1 -24.6%
Current Portion of Long-Term Debt 500.1 1,000.3 -50.0%
Total Current Liabilities 2,823.5 3,330.2 -15.2%
Non-Current Liabilities
Long-Term Debt 5,084.6 5,331.2 -4.6%
Operating Lease Liabilities 682.6 676.3 +0.9%
Finance Lease Liability Noncurrent 63 74.3 -15.2%
Deferred Income Taxes And Other Tax Liabilities Noncurrent 454.5 383.1 +18.6%
Other Non-Current Liabilities 647.8 517.4 +25.2%
Total Liabilities 9,756 10,312.5 -5.4%
Other Liabilities
Noncontrolling Interest Mezzanine Equity 16.9 14.3 +18.2%
Stockholders' Equity
Common Stock 7.5 7.6 -1.3%
Retained Earnings 8,639.9 8,303.4 +4.1%
Accumulated Other Comprehensive Income -27.6 -261.6 +89.4%
Total Stockholders' Equity 8,619.8 8,052.2 +7.0%
Show Equity Components breakouts
Accumulated Other Comprehensive Income -27.6 -261.6 +89.4%
Common Stock 7.5 7.6 -1.3%
Retained Earnings 8,639.9 8,303.4 +4.1%
Total Liabilities & Equity 18,392.7 18,379 +0.1%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q4 2025 YTD Q4 2024 YoY
Operating Activities
Depreciation & Amortization 173 170.6 +1.4%
Stock-Based Compensation 29.7 27.3 +8.8%
Other Operating Activities Cash Flow Statement 19 16.1 +18.0%
Change in Accounts Receivable 4.9 90.9 -94.6%
Increase Decrease In Contract With Customer Asset -0.6 7.6 -107.9%
Change in Inventory -12.3 -14.6 +15.8%
Change in Prepaid & Other Assets -41 -14.7 -178.9%
Change in Accounts Payable 151.6 210.3 -27.9%
Increase Decrease In Deferred Revenue 47.2 3.3 +1330.3%
Increase Decrease In Accrued Liabilities And Other Operating Liabilities -107.3 46.9 -328.8%
Net Cash from Operations 614.2 777.2 -21.0%
Deferred Income Taxes 21.2 38.5 -44.9%
Investing Activities
Capital Expenditures -123.9 -112.1 -10.5%
Payments To Acquire Investments -12.5 -12.7 +1.6%
Proceeds From Sale Of Property Plant And Equipment 4.5 1.4 +221.4%
Payments To Acquire Businesses Net Of Cash Acquired -258 -87.8 -193.8%
Net Cash from Investing -389.9 -209.6 -86.0%
Financing Activities
Repayments Of Senior Debt 0 -400 +100.0%
Proceeds From Accounts Receivable Securitization 0 0 —
Proceeds From Long Term Lines Of Credit 0 0 —
Repayments Of Lines Of Credit 0 0 —
Tax Withholding for Share Compensation -1.3 -7.7 +83.1%
Net Proceeds From Issuance Of Stock To Employees 0 3.2 -100.0%
Payments Of Dividends -59.3 -60.1 +1.3%
Share Repurchases -225 -75.1 -199.6%
Proceeds From Payments For Other Financing Activities -4.8 -7 +31.4%
Net Cash from Financing -290.4 -546.7 +46.9%
Supplemental
Income Taxes Paid 11.4 20.9 -45.5%
Other Cash Flow
Net Change in Cash -65.8 1.4 -4800.0%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key